NLRC5 overexpression
|
Melanoma
|
NLRC5 overexpression
|
Melanoma
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
NLRC5 overexpression
|
Melanoma
|
NLRC5 overexpression
|
Melanoma
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|